Basal cell carcinoma (BCC) is the most common type of skin cancer. Mutations in the Hedgehog (HH) signaling pathway are frequently found in these cancers. Early-stage clinical studies of a HH pathway inhibitor drug have been successful, with 55% of patients reported to respond. However, most tumors change during the course of therapy and drug resistance eventually develops.
Dr. Tang, a dermatologist, will characterize mechanisms of drug resistance and identify new drug combinations that are effective in treatment of BCC. The ultimate goal of her research is to prevent or delay drug resistance. Her studies have the potential to benefit patients with BCC as well as those with other HH-dependent cancers, such as medulloblastoma.
